viral
infect
caus
mani
seriou
human
diseas
high
mortal
rate
new
drugresist
strain
continu
emerg
due
high
viral
mutat
rate
make
necessari
develop
new
antivir
agent
compound
plant
origin
particularli
interest
pentacycl
triterpenoid
pt
divers
class
natur
product
plant
compos
three
terpen
unit
exhibit
antitumor
antiinflammatori
antivir
activ
oleanol
betulin
ursol
acid
repres
pt
wide
present
natur
broad
antivir
spectrum
review
focus
recent
literatur
antivir
efficaci
class
phytochem
deriv
addit
mode
action
also
summar
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
ebola
viru
ebov
given
high
mutat
rate
virus
seriou
threat
public
health
high
urgenc
develop
new
antivir
drug
combat
pathogen
natur
product
root
stem
bark
leav
fruit
seed
plant
use
herbal
medicin
treat
diseas
year
china
also
play
signific
role
modern
drug
discoveri
serv
prototyp
novel
drug
mention
newman
et
al
estim
clinic
use
antitumor
drug
around
end
natur
product
deriv
natur
productderiv
drug
also
crucial
antivir
drug
discoveri
antivir
drug
clinic
use
natur
product
design
use
natur
product
prototyp
among
natur
product
triterpenoid
rel
also
call
steroid
constitut
larg
famili
compound
identifi
molecul
mani
new
compound
discov
plant
anim
fungi
everi
year
exist
natur
free
acid
ester
fatti
acid
ferul
acid
etc
triterpenoid
saponin
link
one
sugar
chain
often
main
activ
constitu
mani
import
medicin
plant
ginsenosid
panax
ginseng
glycyrrhizin
glycyrrhiza
uralensi
saikosaponin
radix
bupleuri
triterpenoid
display
varieti
structur
nearli
differ
skeleton
known
natur
sourc
enzymat
reaction
although
mani
variant
smaller
number
common
structur
type
mani
pentacycl
triterpenoid
pt
show
wide
rang
pharmacolog
activ
market
therapeut
agent
dietari
supplement
structur
pt
four
sixmemb
ring
call
b
c
ring
e
fivememb
sixmemb
base
carbon
skeleton
divid
six
common
subgroup
oleanan
lupan
ursan
friedelan
hopan
gammaceran
fig
pt
larg
class
secondari
plant
metabolit
construct
isopren
c
h
unit
abund
natur
product
plant
linear
triterpen
squalen
major
constitu
shark
liver
oil
deriv
two
farnesyl
pyrophosph
unit
catalysi
squalen
epoxidas
squalen
biosynthet
f
g
u
r
e
chemic
structur
lupeol
amyrin
amyrin
f
g
u
r
e
chemic
structur
pt
oxid
variou
cyclic
product
yield
dammarenyl
lupenyl
baccharenyl
cation
intermedi
eventu
give
rise
three
major
product
name
lupeol
amyrin
amyrin
respect
fig
mani
pt
hydroxyl
group
carboxyl
acid
structur
divers
pt
provid
uniqu
group
agent
varieti
pharmacolog
activ
includ
antivir
antitumor
immunomodulatori
antiinflammatori
hepatoprotect
activ
present
newli
discov
pt
subject
annual
review
reflect
increas
import
class
compound
avail
review
cover
chemistri
antitumor
activ
antiinflammatori
activ
bioavail
pharmacolog
activ
recent
antivir
activ
pt
attract
increas
attent
japan
stronger
neominophagen
c
tm
snmc
prepar
contain
glycyrrhizin
glycyrrhiz
acid
use
treatment
chronic
hepat
diseas
year
glycyrrhetin
acid
ga
fig
pt
deriv
amyrin
type
obtain
hydrolysi
glycyrrhizin
isol
herb
liquoric
show
inhibit
varieti
virus
includ
hepat
b
viru
hbv
hiv
saponin
two
oleananetyp
triterpenoid
isol
soybean
seed
report
activ
hiv
concentr
greater
mgml
respect
three
year
later
chen
et
al
report
salasperm
acid
anoth
oleananetyp
triterpen
deriv
isol
tripterygium
wilfordii
block
replic
hiv
lymphocyt
ic
afterward
fujioka
et
al
found
betulin
acid
ba
isol
leav
bark
syzigium
claviflorum
also
show
signific
activ
hiv
ec
sinc
natur
pt
report
antivir
activ
well
known
lipid
class
hydrophob
biomolecul
import
cellular
life
especi
viru
entri
host
cell
report
promiscu
antivir
activ
natur
pt
might
relat
effect
lipid
metabol
synthet
chemist
becom
interest
scaffold
due
potenti
antivir
properti
lead
product
varieti
pt
deriv
modif
function
group
deriv
use
clinic
drug
treatment
liverrel
diseas
other
variou
phase
clinic
trial
exampl
ba
deriv
bevirimat
bvm
also
known
ba
dsb
found
exhibit
remark
antihiv
activ
primari
drugresist
hiv
isol
repres
uniqu
first
class
antihiv
compound
term
matur
inhibitor
mi
due
baselin
gag
polymorph
posit
reduc
sensit
bevirimat
halt
develop
recent
second
class
potent
pt
develop
oral
treatment
hiv
infect
howev
review
focus
activ
pt
viral
infect
focu
present
review
summar
recent
advanc
antivir
activ
action
model
pt
aid
antivir
drug
develop
pt
hiv
lentiviru
could
lead
hiv
infect
time
acquir
immunodefici
syndrom
aid
lack
cell
hiv
patient
expos
lifethreaten
opportunist
infect
cancer
without
normal
immun
protect
fortun
infect
effect
manag
longterm
administr
multipl
antivir
inhibitor
design
combin
antiretrovir
therapi
cart
sinc
zidovudin
zdv
also
known
azidothymidin
azt
launch
first
antihiv
drug
target
hiv
revers
transcriptas
far
formul
approv
fda
hiv
therapi
howev
none
pt
accord
thomson
reuter
among
chemic
clinic
trial
four
belong
pt
structur
report
literatur
bevirimat
four
compound
mi
bear
scaffold
ba
oral
activ
ba
deriv
target
matur
process
phase
iia
clinic
trial
howev
clinic
test
bevirimat
discontinu
mani
pt
deriv
report
fair
antihiv
activ
usual
show
weaker
antihiv
activ
clinic
avail
drug
howev
enrich
databas
antihiv
compound
provid
good
lead
compound
drug
develop
due
divers
chemic
structur
accord
life
cycl
hiv
inhibitor
hiv
divid
entri
inhibitor
revers
transcriptas
rtase
inhibitor
proteas
inhibitor
viral
mi
tabl
summar
repres
antihiv
pt
base
target
entri
host
cell
first
phase
viral
replic
cycl
order
multistep
process
involv
attach
viru
host
cell
bind
viru
coreceptor
fusion
cell
viral
membran
use
multipl
pathway
entri
usurp
cellular
transport
pathway
surf
along
cell
surfac
process
provid
target
develop
novel
entri
inhibitor
prevent
hiv
infect
first
step
concentr
mm
cell
howev
underli
mechan
kind
compound
remain
unclear
ba
deriv
aminooctanoyl
acid
side
chain
shown
potent
inhibitor
envelopemedi
membran
fusion
ic
valu
compound
vari
rang
nm
cell
system
select
index
excess
transmembran
glycoprotein
initi
report
target
mutat
lai
suffici
drug
resist
studi
illustr
sequenc
loop
stabil
complex
affect
antivir
efficaci
stereoisom
found
equal
activ
ec
valu
interact
chang
structur
acceptor
two
ba
deriv
block
adsorpt
hiv
host
cell
addit
compound
isom
show
highest
activ
magi
fusion
assay
lymphocyt
hiv
rtase
catalyz
replic
viru
rna
dna
inhibit
rtase
enzym
disrupt
essenti
process
viru
replic
infect
therefor
rtase
long
obviou
target
battl
hiv
mimusop
acid
triterpen
analogu
isol
seed
mimusop
elengi
report
possess
weak
hivrtas
inhibitori
activ
ic
micromolar
level
pengsuparp
et
al
report
acid
isol
root
maprounea
africana
also
rtase
activ
ic
valu
hiv
polyprotein
contain
sever
viral
protein
join
togeth
must
cleav
individu
function
protein
cleavag
catalyz
hiv
proteas
symmetr
homodim
inhibit
hiv
proteas
prevent
enzym
cut
viral
protein
molecul
proper
size
make
hiv
proteas
promis
drug
target
ursol
acid
ua
hydrogen
malon
isol
stem
cynomorium
songaricum
activ
inhibit
proteas
ec
valu
micromolar
level
glutaryl
hemiest
ba
ua
shown
proteas
activ
concentr
oleanol
acid
oa
xanthocera
sorbifolia
found
complet
inhibit
proteas
activ
concentr
g
l
chemic
modif
oleananetyp
triterpen
andor
increas
antihiv
proteas
activ
potent
compound
show
antihiv
proteas
activ
ic
rang
addit
escin
ia
ib
two
triterpen
saponin
isol
aesculu
chinensi
also
exhibit
proteas
inhibitori
activ
introduct
group
hydroxyl
oa
gener
potent
compound
dimethylsuccin
greatli
increas
potenc
without
signific
cytotox
compound
shown
activ
subnanomolar
concentr
therapeut
index
similarli
introduct
group
posit
ba
lead
discoveri
bevirimat
compound
greatli
increas
antihiv
activ
ba
ic
valu
less
nm
select
index
structur
report
literatur
oral
bioavail
small
molecul
hiv
therapi
develop
myrexi
block
replic
interrupt
process
viral
capsid
protein
condens
form
conic
core
structur
surround
viral
genom
phase
clinic
trial
healthi
volunt
complet
primari
object
studi
evalu
safeti
toler
pharmacodynam
result
show
overal
safeti
profil
favor
observ
pharmacokinet
pk
pharmacodynam
pd
profil
support
continu
research
develop
firstgener
mi
ineffect
natur
occur
variat
polymorph
gag
proteas
polyprotein
howev
secondgener
inhibitor
develop
better
toler
gag
polymorph
hcv
envelop
positivestrand
rna
viru
genu
hepaciviru
belong
flavivirida
famili
least
six
distinct
genotyp
multipl
subtyp
genotyp
class
import
predict
therapi
respons
hcv
errorpron
replic
process
rna
genom
kb
full
length
encod
singl
polyprotein
amino
acid
cleav
viral
host
enzym
ten
matur
individu
protein
includ
three
structur
protein
core
seven
regulatori
protein
accord
thomson
reuter
antihcv
drug
launch
howev
none
pt
pt
phase
clinic
trial
tabl
summar
repres
antihcv
pt
base
target
propos
hcv
glycoprotein
could
essenti
drug
target
develop
hcv
entri
inhibitor
core
structur
protein
solv
result
mani
agent
investig
inhibitor
interrupt
interact
thu
inhibit
hcv
entri
small
molecul
design
synthes
mimic
interact
space
hydrophob
featur
helix
region
ta
b
l
e
summari
antihcv
pt
base
target
entri
inhibitor
oa
ea
deriv
proteas
inhibitor
oa
deriv
immunomodul
inhibitor
glycyrrhizin
ic
valu
nm
seri
bival
oleananetyp
triterpen
design
synthes
optim
hydrophob
rigid
length
linker
found
compound
exhibit
dramat
enhanc
activ
ic
valu
subnanomolar
rang
well
known
low
solubl
biolog
matrix
high
hydrophob
pt
hinder
applic
particularli
develop
therapeut
agent
given
limit
solubl
pt
seri
triterpenecyclodextrin
cd
conjug
synthes
improv
solubl
maintain
activ
triterpen
base
hcvppvsvgpp
entri
assay
ic
elucid
antihcv
pharmacophor
ea
microbi
transform
strategi
ring
expansionopen
strategi
use
explor
sar
result
show
metabolit
gener
microbi
transform
exhibit
improv
antihcv
activ
except
compound
display
similar
even
littl
higher
potenc
hcv
entri
assay
meanwhil
ring
expans
ring
open
deriv
ea
lacton
acid
pentol
show
improv
antihcv
activ
studi
show
ring
c
ea
highli
conserv
chemic
modif
two
ring
abolish
potenc
suggest
steric
hinder
effect
rigid
skeleton
play
import
role
determin
antihcv
entri
activ
summari
chemic
explor
triterpen
compound
reveal
ring
right
side
ring
e
toler
modif
ring
b
c
left
side
ring
e
highli
conserv
antihcv
entri
activ
introduc
hydroxyl
group
ring
enhanc
potenc
triterpen
remov
hemolyt
effect
ea
fig
oa
also
found
hcv
proteas
inhibitor
base
lead
compound
oa
deriv
synthes
test
inhibitori
activ
hepat
c
viral
proteas
deriv
dicarboxyl
acid
hemiest
show
potent
activ
hcv
proteas
dicarboxyl
acid
hemiest
two
compound
rel
short
carbon
chain
show
much
lower
cytotox
oa
maintain
inhibitori
activ
hcv
proteas
diol
deriv
soyasapogenol
b
inhibit
hcv
replic
induc
oligoadenyl
synthetas
gene
express
enhanc
effect
interferon
ifn
increas
ifnstimul
gene
express
vitro
assay
reduc
hcv
core
antigen
hcvcag
hcvrna
level
mous
liver
moreov
also
found
induc
interleukin
stimul
product
protect
mous
acut
liver
injuryfailur
induc
concanavalin
con
prevent
develop
alcohol
fatti
liver
phase
trial
carri
show
strongli
reduc
posit
neg
rna
strand
level
measur
realtim
polymeras
chain
reaction
pcr
glycyrrhizin
glycyrrhizin
isol
root
licoric
show
broad
antivir
spectrum
tabl
importantli
lead
compound
show
tendenc
induc
resist
influenza
virus
suggest
may
potenti
overcom
antivir
drug
resist
explor
mechan
action
indic
could
block
attach
influenza
viru
particl
membran
host
cell
bind
sialic
acid
receptorbind
pocket
influenza
viral
ha
protein
fig
trior
multival
ligand
show
much
higher
bind
affin
homotrimer
influenza
ha
receptor
recent
group
design
synthes
seri
multival
pt
cd
conjug
enhanc
affin
pt
ha
thu
improv
potenc
influenza
viru
multival
oa
cd
conjug
found
show
potent
antivir
activ
influenza
viru
ic
potent
monoval
oa
cd
conjug
ic
studi
antiinfluenza
action
mechan
show
multival
ptcd
conjug
could
also
bind
influenza
viral
ha
protein
thu
inhibit
attach
influenza
viru
particl
host
cell
fig
recent
among
pt
glycyrrhizin
deriv
first
report
antisarscov
activ
cinatl
et
al
inhibitor
present
ec
effect
sarscov
ec
micromolar
level
deriv
also
demonstr
sever
cytotox
result
decreas
select
index
rang
result
show
chemic
embellish
introduct
conh
bond
abl
enhanc
antiviru
effect
hover
also
found
ga
partial
hydrolyz
exhibit
high
activ
well
toxic
consid
mechan
antisarscov
activ
hover
specul
entri
process
sarscov
cell
block
attach
nacetylglycosamin
carbohydr
sprotein
demonstr
necessari
viral
entri
host
cell
tabl
compar
whose
ec
ryu
cowork
isol
four
quinonemethid
triterpen
triterygium
regelii
compound
smoothli
convert
deriv
hydrogen
palladiumcarbon
catalyst
five
compound
test
sarscov
proteas
inhibitori
activ
tabl
glycyrrhizin
use
treat
hbv
mani
year
vitro
vivo
experi
conduct
test
mechan
action
studi
show
treatment
inhibit
secret
hep
tibetan
herb
potentilla
anserin
l
wide
use
china
treat
hepat
b
compound
fig
fig
herb
evalu
antihsv
activ
vitro
vivo
effect
concentr
plaqu
reduct
wildtyp
hsv
type
respect
therapeut
index
larger
suscept
acyclovir
phosphonoacet
acidresist
thymidin
kinasedefici
wildtyp
hsv
type
similar
wildtyp
indic
broad
antivir
spectrum
hsv
ikeda
et
al
studi
sar
oleananetyp
triterpenoid
includ
glycyrrhizin
sapogenol
result
show
glycyrrhet
acid
sapogenol
glycyrrhizin
much
potent
activ
glycyrrhizin
addit
found
soyasapogenol
show
less
antihsv
activ
soyasapogenol
b
suggest
hydroxyl
might
weaken
antivir
activ
also
found
kudzusapogenol
abrisapogenol
b
abrisapogenol
c
activ
suggest
hydroxyl
group
could
abolish
activ
howev
kudzusapogenol
b
methyl
ester
exhibit
stronger
antihsv
activ
suggest
methyl
ester
group
could
improv
activ
furthermor
gong
et
al
determin
synergist
effect
betulin
acyclovir
drug
combin
studi
potent
moder
synergist
effect
found
acyclovir
betulin
concentr
higher
respect
synergist
effect
also
found
concentr
acyclovir
betulin
respect
synergist
antivir
effect
suggest
action
mechan
betulin
differ
acyclovir
glycyrrhizin
one
main
compon
isol
glycyrrhiza
spp
mani
kind
antivir
activ
wang
studi
first
recogn
medicin
effect
compound
inhibit
replic
dosedepend
manner
concentr
requir
inhibit
infect
millimolar
rang
reduc
infecti
product
mm
mm
respect
addit
iden
si
valu
greater
strong
activ
low
cytotox
indic
potenti
use
treat
infect
tabl
furthermor
action
hr
indic
inhibitori
effect
occur
infect
replic
process
therefor
may
potenti
prevent
effect
well
treatment
effect
song
et
al
report
hederasaponin
b
fig
hedera
helix
activ
compound
could
significantli
decreas
format
visibl
cpe
vero
cell
demonstr
effect
activ
without
obviou
cytotox
tabl
addit
western
blot
assay
show
abl
reduc
express
viral
protein
thu
demonstr
inhibitori
effect
synthesi
viral
capsid
protein
comparison
ribavirin
show
activ
result
indic
promis
drug
candid
variou
subgenotyp
broad
spectrum
antivir
activ
zhao
et
al
evalu
six
newli
synthes
pt
activ
analyz
inhibitori
effect
express
protein
western
blot
analysi
revers
transcript
rt
pcr
compound
demonstr
potent
activ
parent
compound
signific
cytotox
found
epsteinbarr
viru
ebv
one
major
pathogen
infecti
mononucleosi
human
gener
link
two
malign
endem
burkitt
lymphoma
nasopharyng
carcinoma
npc
number
ebvassoci
diseas
increas
requir
develop
effect
vaccin
protect
well
novel
antivir
agent
treatment
lin
et
al
report
glycyrrhizin
exhibit
activ
ebv
replic
superinfect
raji
cell
dosedepend
manner
ic
mm
cc
mm
si
time
addit
studi
show
antieb
effect
close
associ
event
post
viru
cell
entri
rather
direct
inactiv
viru
block
viru
adsorpt
antivir
mechan
appear
earli
step
ebv
replic
cycl
differ
mechan
nucleosid
analog
target
viral
dna
polymeras
deriv
repres
new
type
antiebv
agent
chang
cowork
first
report
moron
acid
isol
gall
brazilian
propoli
rhu
chinensi
agent
eb
viru
compar
triterpen
novel
antieb
mechan
immediateearli
stage
lytic
cycl
ebv
transcript
viral
lytic
gene
activ
rta
pt
class
plant
metabolit
high
structur
divers
provid
import
sourc
lead
compound
drug
research
develop
pt
deriv
use
prevent
treat
chronic
hepat
diseas
mani
countri
china
japan
addit
gener
show
weak
toxic
howev
valu
pt
prevent
treat
viral
diseas
partial
exploit
bevirimat
investig
molecular
basi
antivir
activ
also
progress
rapidli
howev
precis
target
action
mechan
usual
unclear
limit
develop
addit
poor
aqueou
solubl
anoth
major
drawback
variou
applic
particular
develop
drug
intens
explor
lead
design
new
pt
potent
antivir
inhibitor
better
antivir
activ
profil
lower
ic
valu
also
like
express
regret
relev
research
cite
review
due
limit
space
http
